Why This Early-Stage Autoimmune and Chonic Inflamatory Trial May Be a Big Hit24/7 Wall Street • 11/11/19
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer MeetingThe Motley Fool • 10/09/19
Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'Benzinga • 10/08/19
Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buyMarket Watch • 10/08/19
Biotech Crashes 35% After Bad Drug Likely Skewed Cancer Drug TestsInvestors Business Daily • 08/09/19
Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer DrugBenzinga • 08/09/19